+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 17 Actively Recruiting clinical trials

C

Actively Recruiting

Healthy Volunteer

This research evaluates the bioavailability, safety, and tolerability of two formulations of Torasemide 10 mg tablets in healthy adults under fasting conditions. It is a Phase I study comparing the test medication by Berlin-Chemie AG to Unat4 10 tablets by Viatris Healthcare GmbH to determine if the two formulations are bioequivalent. Participants receive a single 10 mg dose of either Torasemide 10 mg tablet by Berlin-Chemie AG or Unat4 10 tablets by Viatris Healthcare GmbH, orally with 240 mL of water while fasting. The study uses a randomized, open-label, single-dose, two-treatment, two-period, two-sequence crossover design, where each participant receives both treatments in separate periods. During the study, researchers measure the maximum concentration C max and area under the curve AUC 0-last over 24 hours to assess bioavailability. Additional measures include other pharmacokinetic parameters such as T max, half-life, and elimination rate. Participants undergo clinical and laboratory assessments to confirm health status and monitor safety. The total participation time and follow-up duration span up to one year for secondary outcomes.

Age: 18Years - 55YearsAll GendersPhase 1
1 location
P

Actively Recruiting

Researchers are conducting a Phase 2, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of three different dose regimens of MORF-057 in adults with moderately to severely active Crohns disease CD. The study aims to assess how well MORF-057 works compared to placebo during induction therapy in this patient population. The trial is conducted across multiple centers and includes adults aged 18 to 85 years with active CD as defined by clinical and endoscopic criteria. Participants will be randomly assigned to one of three blinded groups receiving different doses of MORF-057 or matching placebo during a 14-week Induction Period. Following this, all participants will receive open-label MORF-057 during a 38-week Maintenance Period. Those who complete the full 52-week treatment phase may continue treatment in a 52-week Long-Term Extension to further assess long-term effects. Throughout the study, participants will undergo assessments including the Simple Endoscopic Score for Crohns Disease SES-CD at week 14 to measure endoscopic response, and the Crohns Disease Activity Index CDAI to evaluate clinical response and remission. Safety and tolerability will be monitored regularly. The total study duration for participants can extend up to 104 weeks including the extension phase, with frequent visits and evaluations to monitor disease activity and treatment effects.

Age: 18Years - 85YearsAll GendersPhase 2
224 locations
O

Actively Recruiting

Researchers are studying adults in Kazakhstan who have metabolic dysfunction-associated steatotic liver disease MASLD to better understand how this liver condition appears and is managed in everyday medical care. The study includes about 420 adults with MASLD, focusing on their health characteristics and how the disease affects them. A smaller group of about 65 participants in Almaty, who were already prescribed Ursosan by their doctors, will be followed to observe changes in liver-related health measures. The study has two parts a cross-sectional component where information from medical records, lab tests, liver imaging, and questionnaires is collected once for each participant and a prospective cohort component that follows the subgroup receiving Ursosan for approximately six months. During this follow-up, participants will have remote contacts at about 2 and 4 months and a final assessment at 6 months. Treatment decisions, including the use of Ursosan, are made by the participants doctors as part of routine care, not assigned by the study. Participants will provide data through routine medical care records, imaging scans, laboratory tests, and questionnaires about lifestyle and health. Researchers will measure liver health through imaging, liver enzyme levels, and fibrosis assessments. The study monitors changes in these measures over time, especially in the Ursosan subgroup. Participation may last up to six months for some, while others contribute data at a single time point, helping researchers understand MASLD and responses to Ursosan in real-world settings.

Age: 18Years - 65YearsAll Genders
7 locations
E

Actively Recruiting

Researchers are evaluating whether adding the NutriSteppe digital dietary intervention to routine medical care improves metabolic health in adults aged 21 to 65 years who have type 2 diabetes, obesity, or are overweight with related health issues. Participants in this study are already receiving or have been prescribed glucagon-like peptide-1 GLP-1 receptor agonist therapy by their doctors outside of this trial. The main goal is to see if the NutriSteppe app improves glycated hemoglobin HbA1c, a measure of average blood glucose, after 12 weeks compared to routine care alone. Participants are randomly assigned to one of two groups. Both groups continue their routine medical care including GLP-1 receptor agonist therapy. The control group receives general lifestyle advice, while the intervention group uses the NutriSteppe mobile app, which provides personalized meal planning, food diaries, nutritional analysis, educational modules, reminders, and dietary recommendations for 12 weeks. All participants photograph their food and drink, and these photos are analyzed by an automated system called Tagam-AI. Only the intervention group receives personalized dietary advice based on this analysis. During the study, participants attend visits for examinations, laboratory tests, and questionnaires. Researchers measure changes in HbA1c, fasting glucose, body weight, body mass index, waist circumference, cholesterol levels, blood pressure, diet quality, quality of life, and dietary adherence. Safety is monitored by tracking adverse events and laboratory parameters. Participants use the NutriSteppe app at least five days per week and record body weight weekly. The total participation lasts 12 weeks with regular assessments throughout.

Age: 21Years - 65YearsAll GendersPhase Not Applicable
1 location
S

Actively Recruiting

Researchers are investigating the health outcomes of children conceived through advanced assisted reproductive technologies ART such as intracytoplasmic sperm injection ICSI and frozen embryo transfer FET. The study aims to understand the effects of these methods on the physical growth, cognitive development, and reproductive health of children up to three years old, exploring potential deviations from typical health norms. This observational project also considers maternal medication use during pregnancy and paternal infertility factors. The research involves multiple assessments including retrospective analysis of medical histories, measurement of physical growth parameters like weight, height, and head and chest circumference, and evaluation of psychomotor development using standardized tests like the Griffiths Mental Development Scale and Denver Developmental Screening Tests. Male children conceived via ICSI will undergo examinations by pediatric andrologists, including ultrasounds and hormone level evaluations such as Inhibin B and Anti-Mllerian Hormone AMH. Data collection incorporates clinical exams, lab tests, and parental medical histories to build a comprehensive health profile. Participants will have a single clinical assessment up to 36 months of age, during which physical growth, neurodevelopmental status, and reproductive health will be measured. Neurosonography will be used for children under one year to assess brain structure. Researchers will analyze data using statistical methods to identify health patterns and risk factors, aiming to develop predictive models and management algorithms for children conceived via ART. The study emphasizes ethical standards, including informed parental consent and data confidentiality, with findings intended to improve clinical care and health outcomes for this population.

Age: 0Months - 3YearsAll Genders
1 location
P

Actively Recruiting

Healthy Volunteer

Researchers are exploring ways to improve personalized and preventive care for non-communicable diseases such as cardiovascular diseases, type 2 diabetes, chronic respiratory diseases, obesity, and chronic kidney diseases in Kazakhstan. This observational study focuses on understanding epigenetic factors and uses machine learning models to predict biological age and reproductive function, aiming to tailor health recommendations for individuals. The study involves one cohort divided into four age groups 18-29 years, 30-44 years, 45-59 years, and 60-69 years, with an equal number of men and women in each group. Participants will undergo genetic investigations including DNA analysis to examine telomere length and DNA methylation levels. Data collection and model predictions will take place within ten months from the start of the study. Participants will be residents of Kazakhstan aged 18 to 69 years who consent to participate. The study will monitor the accuracy of machine learning models in predicting biological age and reproductive function. All data collection will be observational, with no treatments administered. The total participation timeline includes data collection and assessment periods within the planned study duration ending in 2026.

Age: 18Years - 69YearsAll Genders
1 location
N

Actively Recruiting

Researchers are evaluating the expansion of opioid agonist therapies OAT in Central Asia to address the rapidly growing HIV epidemic, primarily affecting people who inject drugs PWID and their sexual partners. This health services research focuses on scaling up OAT in Kazakhstan, Kyrgyzstan, and Tajikistan using the Network for the Improvement of Addiction Treatment NIATx strategy guided by the Exploration-Planning-Implementation-Sustainment EPIS framework. The study aims to understand and improve OAT delivery in these countries with low coverage and multiple barriers. The intervention involves training and coaching national experts and Chief Narcologists from regions within the three countries through NIATx, which includes in-depth coaching, collaborative learning, and quality improvement tools. Participants will engage in formative research, organizational assessments, and focus groups to identify barriers and facilitators to OAT entry and retention. The approach is tailored to local contexts and aims to create sustainable OAT models integrated into primary and HIV clinical care. Participants will be involved in surveys, focus groups, and organizational assessments over a 36-month period, with data collected on OAT census, new patient enrollments, and dropout rates by region. The study includes ongoing stakeholder meetings to guide implementation and policy changes for sustainability. The primary outcomes focus on OAT scale-up and retention, with secondary outcomes tracking new patient numbers and dropout rates, aiming to build regional expertise and support long-term program success.

Age: 18Years +All GendersPhase Not Applicable
4 locations
C

Actively Recruiting

Researchers are evaluating ten different vitreoretinal surgical techniques for repairing full-thickness macular holes, a condition that threatens vision. This study aims to identify which surgical method leads to the highest rate of hole closure as seen on optical coherence tomography OCT and the best visual outcomes. The trial includes adults with varying sizes of macular holes and uses stratified randomization based on hole size to balance participant groups. The study involves pars plana vitrectomy PPV procedures with various approaches, such as internal limiting membrane ILM peeling, different ILM flap configurations, adjunct use of autologous platelet-rich plasma PRP, human amniotic membrane hAM grafts, and macular edge hydrodissection. Participants are randomly assigned to one of the ten surgical techniques. Postoperative care and follow-up are standardized across all groups. Participants will have follow-up visits on Day 7, Month 1, and Year 1 after surgery to undergo clinical exams and OCT imaging to assess macular hole closure, visual acuity, and safety outcomes including complications and reoperations. The study will measure anatomical closure on OCT at these time points as the primary outcome, along with secondary outcomes like best-corrected visual acuity and morphological recovery. Safety and adverse events will be monitored through the first year post-surgery.

Age: 18Years +All GendersPhase Not Applicable
1 location
O

Actively Recruiting

Researchers are studying approximately 240 adult patients in Kazakhstan who have HER2-positive metastatic breast cancer mBC and are receiving anti-HER2 therapy, excluding trastuzumab deruxtecan. This observational retrospective study aims to evaluate real-world treatment approaches, clinical outcomes, and patient characteristics across 12 oncology centers to provide a representative sample of this population. The study covers patients diagnosed with mBC between January 2022 and December 2023 and includes a follow-up period to assess treatment impact. The study collects data retrospectively from patient medical records starting from the date of mBC diagnosis until either the patients death or the end of the study, which is at least 12 months after the latest diagnosis date. The treatments under review include all anti-HER2 therapies except trastuzumab deruxtecan. Researchers will analyze treatments received, diagnostic methods, therapy discontinuation reasons, lines of anticancer therapy, and efficacy in routine clinical practice. Participants data will be reviewed for at least 24 months following diagnosis, unless the patient died, moved, or refused therapy within that period. The primary outcome is to assess median progression-free survival and its rate over up to two years. Secondary outcomes include describing patient demographics, diagnostic and therapeutic patterns, treatment approaches, efficacy, reasons for stopping therapy, and number of therapy lines. This design involves no direct intervention, and data collection is based on existing medical records.

Age: 18Years - 99YearsAll Genders
12 locations
G

Actively Recruiting

This research aims to collect real-world data on patients with type 2 diabetes, hypertension, heart failure, and chronic kidney disease. It focuses on understanding patient characteristics, disease management, healthcare use, and outcomes across many countries. The study is an observational registry that includes patients seen in regular clinical practice worldwide. Participants are grouped based on their main condition or comorbidities, including type 2 diabetes, hypertension, chronic kidney disease, or heart failure. Data is collected both retrospectively and prospectively using a cloud-based electronic case report form accessible to investigators and a scientific committee. The registry is open to all physicians managing these conditions globally. Participants contribute information about their health status, treatments, and clinical measurements over time. Researchers gather demographic data, disease history, lab tests, imaging, medication use, healthcare visits, and outcomes such as hospitalizations and complications. The study measures many health indicators at baseline and averages over three years to understand care quality and disease progression. Participation can last until the study ends in 2030.

Age: 18Years +All Genders
76 locations

1-10 of 17

1